Journal Article
. 2015 Aug;121(22).
doi: 10.1002/cncr.29621.

Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years

Arnold L Potosky 1 Suzanne C O'Neill 1 Claudine Isaacs 1 Huei-Ting Tsai 1 Calvin Chao 2 Chunfu Liu 3 Bola F Ekezue 3 Nandini Selvam 3 Larry G Kessler 4 Yingjun Zhou 1 Marc D Schwartz 1 
Affiliations
  • PMID: 26291519
  •     20 References
  •     14 citations

Abstract

Background: Gene expression profiling (GEP) testing can help to predict the risk of cancer recurrence and guide decisions about adjuvant chemotherapy for breast cancer (BC). However, no prior US studies have evaluated the relation between GEP testing and the use of adjuvant chemotherapy by women treated in a general oncology practice.

Methods: Eligible patients were women under the age 65 of years who were newly diagnosed with their first stage I or II, hormone receptor-positive BC between 2006 and 2011 (n = 9405). This retrospective study was conducted with a data set consisting of registry data, health claims data, and GEP testing results. The distribution of GEP test results was reported in terms of the risk of recurrence predicted, and logistic regression was used to assess the association of test results with chemotherapy use, with adjustments made for multiple patient characteristics.

Results: The proportions of tested women with low, intermediate, and high recurrence score results were 51%, 39%, and 10%, respectively. Among these women, 11%, 47%, and 88%, respectively, received adjuvant chemotherapy. There was a significant, positive linear relation of assay scores with chemotherapy use within the low and intermediate subgroups after adjustments for all other factors (adjusted odds ratios, 1.17 and 1.20, respectively).

Conclusions: Adjuvant chemotherapy use after GEP testing is generally consistent with the recommended test interpretation for women with a high or low predicted risk of recurrence. Chemotherapy use in the intermediate-risk group increased with Recurrence Score values, and evidence from ongoing randomized trials may help to clarify whether this finding reflects optimal interpretation of GEP test results. These results demonstrate the principle that genomic testing, on the basis of research establishing its utility, can be applied appropriately in general practice in accordance with guideline recommendations.

Keywords: breast neoplasms; chemotherapy; gene expression profiling; population-based studies; practice patterns.

Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.
Scott D Ramsey, William E Barlow, +6 authors, Gabriel N Hortobagyi.
Contemp Clin Trials, 2012 Sep 25; 34(1). PMID: 23000081    Free PMC article.
Review.
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
Adjuvant chemotherapy use and outcomes in older women with breast cancer: what have we learned?
Rebecca A Silliman, Patricia A Ganz.
J Clin Oncol, 2006 Jun 20; 24(18). PMID: 16782908
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
Catherine M Kelly, Savitri Krishnamurthy, +4 authors, Lajos Pusztai.
Cancer, 2010 Jul 29; 116(22). PMID: 20665886
The influence of a gene expression profile on breast cancer decisions.
Leonard R Henry, Alexander Stojadinovic, +3 authors, Peter W Soballe.
J Surg Oncol, 2009 Feb 11; 99(6). PMID: 19204954
21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.
Mary Jo Lund, Marina Mosunjac, +7 authors, Ruth M O'Regan.
Cancer, 2011 Jul 02; 118(3). PMID: 21720988
Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer.
A J Nixon, D Neuberg, +7 authors, J R Harris.
J Clin Oncol, 1994 May 01; 12(5). PMID: 8164038
Highly Cited.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Long-term complications of adjuvant chemotherapy for early stage breast cancer.
Ann H Partridge, Eric P Winer.
Breast Dis, 2005 Feb 03; 21. PMID: 15687723
Review.
Comorbidity measures for use with administrative data.
A Elixhauser, C Steiner, D R Harris, R M Coffey.
Med Care, 1998 Feb 07; 36(1). PMID: 9431328
Highly Cited.
Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.
Piiha-Lotta Jerevall, Sara Brommesson, +7 authors, Olle Stål.
Breast Cancer Res Treat, 2007 Apr 25; 107(2). PMID: 17453342
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Laura Zanotti, Alberto Bottini, +2 authors, Maria Rosa Cappelletti.
Tumour Biol, 2014 Jul 23; 35(9). PMID: 25048969
Review.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Josh J Carlson, Joshua A Roth.
Breast Cancer Res Treat, 2013 Aug 27; 141(1). PMID: 23974828    Free PMC article.
Highly Cited. Systematic Review.
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
Gary H Lyman, Leon E Cosler, Nicole M Kuderer, John Hornberger.
Cancer, 2007 Feb 22; 109(6). PMID: 17311307
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.
Ruth Oratz, Dev Paul, Allen L Cohn, Scot M Sedlacek.
J Oncol Pract, 2007 Jul 01; 3(4). PMID: 20859407    Free PMC article.
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
Aron Goldhirsch, William C Wood, +3 authors, Hans-Jörg Senn.
J Clin Oncol, 2003 Jul 09; 21(17). PMID: 12847142
Highly Cited. Review.
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Underutilization of gene expression profiling for early-stage breast cancer in California.
Rosemary D Cress, Yingjia S Chen, +2 authors, Kenneth W Kizer.
Cancer Causes Control, 2016 Apr 22; 27(6). PMID: 27097910    Free PMC article.
Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.
Anosheh Afghahi, Maya Mathur, +14 authors, Allison W Kurian.
J Oncol Pract, 2016 May 26; 12(6). PMID: 27221993    Free PMC article.
21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
Benjamin M Parsons, Jeffrey Landercasper, +3 authors, Leah L Dietrich.
Breast Cancer Res Treat, 2016 Aug 11; 159(2). PMID: 27507245    Free PMC article.
Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.
Christopher R Friese, Yun Li, +6 authors, Steven J Katz.
Cancer, 2016 Oct 25; 123(1). PMID: 27775837    Free PMC article.
The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.
Yun Li, Allison W Kurian, +6 authors, Timothy P Hofer.
Breast Cancer Res Treat, 2016 Dec 25; 161(3). PMID: 28012085    Free PMC article.
Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65.
Suzanne C O'Neill, Claudine Isaacs, +8 authors, Arnold L Potosky.
Breast Cancer Res, 2017 Apr 01; 19(1). PMID: 28359319    Free PMC article.
Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
Allison W Kurian, Irina Bondarenko, +7 authors, Steven J Katz.
J Natl Cancer Inst, 2017 Dec 14; 110(5). PMID: 29237009    Free PMC article.
Cost Effectiveness of Gene Expression Profile Testing in Community Practice.
Young Chandler, Clyde B Schechter, +8 authors, Jeanne S Mandelblatt.
J Clin Oncol, 2018 Jan 09; 36(6). PMID: 29309250    Free PMC article.
Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.
Tanja Ovcaricek, Iztok Takac, Erika Matos.
Radiol Oncol, 2019 Sep 26; 53(3). PMID: 31553709    Free PMC article.
Review.
Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.
Lindsay J Collin, Ming Yan, +8 authors, Lauren E McCullough.
NPJ Breast Cancer, 2019 Oct 05; 5. PMID: 31583272    Free PMC article.
Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
Angela Mariotto, Jinani Jayasekerea, +5 authors, Jeanne S Mandelblatt.
J Natl Cancer Inst, 2019 Jun 06; 112(2). PMID: 31165854    Free PMC article.
Automated volumetric radiomic analysis of breast cancer vascularization improves survival prediction in primary breast cancer.
Matthias Dietzel, Rüdiger Schulz-Wendtland, +7 authors, Pascal A T Baltzer.
Sci Rep, 2020 Mar 01; 10(1). PMID: 32111898    Free PMC article.
Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives.
Suzanne C O'Neill, Kathryn L Taylor, +5 authors, Jeanne Mandelblatt.
J Health Commun, 2018 Aug 22; 23(7). PMID: 30130477    Free PMC article.
Combination of circulating miR-145-5p/miR-191-5p as biomarker for breast cancer detection.
Yeldar Ashirbekov, Arman Abaildayev, +7 authors, Nagima Aitkhozhina.
PeerJ, 2020 Dec 29; 8. PMID: 33362968    Free PMC article.